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ABSTRACT This study was conducted in 2004 to evaluate the prevalence of hepatitis B (HBV), hepatitis 
C (HBC) and human immunodeficiency (HIV) virus infection in 133 injecting drug users (IDUs) attending 
a voluntary rehabilitation centre in Shahr-e-Kord, and to identify risk factors for these infections in this 
group. Serum samples were screened for HBV, HCV and HIV infection. Only 1 participant (0.8%) was 
HIV positive, 15 (11.2%) were HCV positive and 8 (6.0%) were positive for HBV surface antigen. There 
was significant correlation between using shared syringes and infection with HIV, HCV and HBV. 
Séroprévalence des infections VIH, VHB et VHC chez des toxicomanes par voie intraveineuse à 
Shahr-e-Kord (République islamique d’Iran) 
RÉSUMÉ Cette étude a été menée en 2004 dans l’objectif d’évaluer la prévalence des infections par le 
virus de l’hépatite B (VHB), le  virus de l’hépatite C (VHC) et  le virus de l’immunodéficience humaine 
(VIH) chez 133 toxicomanes par voie intraveineuse fréquentant un centre de désintoxication associatif 
de Shahr-e-Kord, et de cerner les facteurs de risque de ces infections dans ce groupe. Un dépistage 
des infections VIH, VHB et VHC a été réalisé sur les échantillons de sérum. Seul un participant (0,8 %) 
était positif au VIH, 15 (11,2 %) étaient positifs au VHC et 8 (6,0 %) étaient positifs aux Ag HBs. Il 
existait une corrélation significative entre le partage de seringues et les infections par le VIH, le VHC 
et le VHB. 
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Introduction 
Injecting drug users (IDUs) constitute a 
group frequently exposed to a number of vi-
ral infections since they frequently engage 
in high risk behaviour [1]. Hepatitis C virus 
(HCV), hepatitis B virus (HBV) and human 
immunodeficiency virus (HIV) share the 
common features of having a lipid envelope 
and being transmitted by blood contact [2]. 
Consequently, sharing injection equipment 
such as needles has been implicated as one 
of the most significant risk factors in the 
transmission of these infections in IDUs 
[3–5]. The prevalence of bloodborne hepa-
titis is usually higher among IDUs than in 
comparable non-IDU groups in the popula-
tion [6].
There is some evidence indicating high 
prevalence rates of bloodborne infections 
among IDUs in different parts of Asia [7–
9]. Epidemiological data indicate that IDUs 
represent the largest at-risk group for HCV 
infection [10]. Both HCV and HBV infec-
tions are of major public health concern: 
infected individuals carry a substantial risk 
of chronic liver disease, 5%–10% for HBV 
and > 50% for HCV. Moreover, individuals 
infected with HBV, and to a lesser degree 
HCV, may transmit the virus to their sexual 
partners, and in the case of females to their 
offspring [6,10]. It is now recognized as 
being extremely important to prevent HCV 
infection among groups at high risk of 
HIV infection as it frequently progresses to 
chronic hepatitis, cirrhosis and eventually 
hepatocellular carcinoma [6,10]
HIV infection is one of the most impor-
tant public health concerns. A variety of spe-
cific risk factors of HIV infection in humans 
such as needle sharing and number of drug 
injections have been identified. Significant 
outbreaks of HIV infection among IDUs 
have occurred in about half the countries in 
North Africa and the Middle East, notably 
in the Islamic Republic of Iran, where 65% 
of reported HIV cases have been attributed 
to injecting drug use [11]. A recent study 
showed the most common route of infection 
in IDUs was via shared syringes [12]. The 
proportion of IDUs in different parts of the 
Islamic Republic of Iran varies, but no data 
were available for Shahr-e-Kord: people 
tend to conceal their addiction from others 
because it is considered very serious and 
reprehensible, and quite shameful in our 
culture.
In order to implement appropriate pre-
vention measures, it is important to identify 
specific risk factors for HBV, HCV and 
HIV infection among IDUs based on epide-
miological data. In view of the limited data 
on the epidemiology of bloodborne viral 
infections among IDUs in our country, this 
study was undertaken to assess the preva-
lence of HBV, HCV and HIV infections 
and their respective risk factors among this 
group in Shahr-e-Kord, a city in the south 
west of the Islamic Republic of Iran with a 
population of about 400 000.
Methods
The study sample comprised all those (133 
IDUs) who enrolled in the State Welfare 
Organization of Iran, a voluntary reha-
bilitation centre, from July 2004 to October 
2004. All were informed about the study 
and agreed to participate. This rehabilitation 
centre is unique in this city. Its services are 
available to addicted people to help them to 
overcome their addiction using medical and 
psycho-social methods. 
The sample size and estimated IDU rate 
were adequate for such studies (P = 0, alpha 
= 0.05, d = 0.05 gives calculated sample 
size of 144). The sex ratio was, however, 
skewed because of cultural and other limita-
tions on females.
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In this centre, serum samples from IDUs 
were tested for HCV and HIV specific anti-
bodies and HBV surface antigen (HBsAg). 
Serum samples were screened in the 
research laboratory of Shahr-e-Kord Uni-
versity of Medical Sciences for HBsAg, 
HCV and HIV specific antibodies by 
enzyme-linked immunosorbent assay (Or-
ganon Teknika HTLV-1/II Vironostika). 
All HIV positive samples were confirmed 
by Western blot (GeneLabs Diagnostics 
Ltd).
Information on demographics and HCV, 
HBV- and HIV-related risk behaviours was 
obtained from each participant through an 
interviewer-assisted questionnaire. Data 
were collected on sociodemographic status, 
history of incarceration and using shared 
syringes. Statistical analysis and data merg-
ing were carried out using SPSS, version 
10. Results were regarded as significant at 
P < 0.05. Descriptive results were presented 
as frequencies, ratios and 95% confidence 
intervals. Correlation between different 
factors was evaluated using the chi-squared 
test.
Results
The study sample comprised 131 (98.4%) 
males and 2 (1.5%) females, with a mean 
age of 31.3 (standard deviation 7.1; range 
18–65) years.
Seroprevalence of anti-HCV, HBsAg 
and anti-HIV
The prevalence of anti-HCV, HBsAg and 
anti-HIV in IDUs is shown in Table 1. Of 
the 133 IDUs studied, 15 (11.3%) were 
HCV positive, 8 (6.0%) were HBsAg posi-
tive and 1 (0.8%) was HIV positive. Neither 
of the 2 females was positive for anti-HCV, 
anti-HIV and HBsAg. 
Analysis of individual risk factors
The mean age of HCV positive and HBV 
positive IDUs was 33.4 and 31.1 years, 
respectively. The mean age of those with 
HCV, HBV and HIV was 31.0, 31.3 and 
31.4 years respectively. 
Many of the HCV+, HBV+ and HIV+ 
IDUs used shared syringes and had a his-
tory of ≥ 1 previous incarceration (Table 
2). Using the chi-squared test, there was 
significant correlation between using shared 
syringes and infection with both HCV and 
HBV (P < 0.05). 
Discussion
IDU is a key factor in the transmission of 
bloodborne pathogens. It has been shown 
that both injection-related risk factors, dura-
tion of injecting drugs, type of drug injected 
and direct and indirect sharing of injection 
are conducive to the spread of HIV, HBV, 
and HCV among IDUs [13]. 
It has been reported that 65% of the 
known and reported HIV cases in the Is-
Table 1 Distribution of males and females in 
the study sample according to anti-HIV, anti-
HCV and anti-HBsAg status
Infection Total Males Females
  No. % No. % No. %
HCV+ 15 11.3 15 11.5 0 –
HCV– 118 88.7 116 88.5 2 100.0
HBsAg+ 8 6.0 8 6.1 0 –
HBsAg– 125 94.0 123 93.9 2 100.0
HIV+ 1 0.8 1 0.8 0 –
HIV– 132 99.2 130 99.2 2 100.0
HCV = hepatitis C virus; HBsAg = hepatitis B surface 
antigen; HIV = human immunodeficiency virus.
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lamic Republic of Iran have been attributed 
to injection drug use [11]. Also prevalence 
of HIV in IDUs in Fars province has been 
estimated at 30% [12]. Taking this into con-
sideration, it is possible that in our study, 
the first prevalence study of bloodborne 
infections among IDUs in Shahr-e-Kord, 
we may have underestimated the prevalence 
of HIV infection. Nevertheless, our results 
also showed that the number of IDUs who 
shared syringes/needles was lower than the 
number who did not share: this could be an 
alternative explanation for the low rate of 
HIV infection.
The relatively low rate of HBV infection 
we found compared with the rates found 
(5%–61.4%) in some other studies [14–17] 
could be due to the use of the HBsAg test. 
Using this test, only 6.2% of the cases were 
positive (Table 1). Since any exposure to 
hepatitis B virus would have resulted in 
a positive test for anti-HBc (antibody to 
hepatitis B core antigen) [16], it is possible 
more samples may have tested positive us-
ing this test.
In our study, HCV prevalence rate was 
11.2%, which was much lower than that 
reported (33%–96.8%) from countries such 
as Italy, Syria and Taiwan [17–21] and also 
lower than in a previous study from Fars 
province (78%) [12]. Again, this difference 
may have been due to technical limitations 
which could have led to underestimation of 
this infection. In spite of this difference, the 
IDU population in our province is at high 
risk for HCV infection and its sequelae. 
We identified history of syringe sharing 
as an important determinant of HBV, HCV 
and HIV infection as there was significant 
correlation between sharing syringes and 
infection with HIV, HCV and HBV. This 
corroborates the findings of previous stud-
ies indicating that use of shared syringes 
by IDUs render them at high risk of these 
infections [22–24]. Our findings provide 
further confirmatory evidence indicating 
that this behaviour is the main risk factor for 
these infections.
In spite of the low prevalence of the 3 
main bloodborne infections found in this 
Table 2 HBV-, HCV- and HIV-related risk behaviours in injecting drug 
users in Shahr-e-Kord
Antibody Ever shared syringe/needle Previous incarceration
  Yes (n = 26) No (n = 107) Yes (n = 47) No (n = 86)
  No. % No. % No. % No. %
HCV+ 8* 30.8 7 6.5 8 17.0 7 8.1
HCV– 18 69.2 100 93.5 39 83.0 79 91.9
HBsAg+ 5* 19.2 3 2.8 4 8.5 4 4.7
HBsAg– 21 80.8 104 97.2 43 91.5 82 95.3
HIV+ 1 3.8 0 0.0 1 2.1 0 0.0
HIV– 25 96.2 107 100.0 46 97.9 86 100.0
*P < 0.05.
HCV+ and shared syringe/needle P = 0.002.
HBsAg+ and shared syringe/needle P = 0.007.
HCV+ and previous incarceration P = 0.105.
HBsAg+ and previous incarceration P = 0.269.
HCV = hepatitis C virus; HBsAg = hepatitis B surface antigen; HIV = human 
immunodeficiency virus.
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study, owing to increasing number of IDUs 
in Iran [25], harm reduction programmes are 
needed to halt the spread of HIV, HBV and 
HCV infection. In particular, the capacity 
of syringe-exchange programmes to refer 
participants to drug treatment programmes 
and facilitate access to health and social 
services needs to be increased. 
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HIV prevention and care among injecting drug users in the Islamic 
Republic of Iran. A review of best practice
The above-mentioned document reviews the implementation of 
harm reduction programmes, care and support services for people 
living with HIV/AIDS, and the attempts to reach and deliver services 
to hidden populations of injecting drug users in the Islamic Republic 
of Iran. It is intended for programme managers and policy-makers in 
all countries in order to share the Iranian experience as a model for a 
comprehensive approach to introducing and scaling up harm reduc-
tion. In addition to identifying harm reduction programme elements 
and their implementation, the document can also be a useful resource 
for advocacy.
The document is available on line at: http://www.emro.who.int/asd/pdf/
hiv_review_iran.pdf.
